
==== Front
Curr Osteoporos Rep
Curr Osteoporos Rep
Current Osteoporosis Reports
1544-1873
1544-2241
Springer US New York

38236512
851
10.1007/s11914-023-00851-1
Article
Mind Gaps and Bone Snaps: Exploring the Connection Between Alzheimer’s Disease and Osteoporosis
Wang Hannah S. 1
Karnik Sonali J. 1
Margetts Tyler J. 1
Plotkin Lilian I. 234
Movila Alexandru 35
Fehrenbacher Jill C. 367
Kacena Melissa A. mkacena@iupui.edu

1234
Oblak Adrian L. aoblak@iupui.edu

78
1 https://ror.org/02ets8c94 0000 0001 2296 1126 Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN 46202 USA
2 https://ror.org/02ets8c94 0000 0001 2296 1126 Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN 46202 USA
3 https://ror.org/02ets8c94 0000 0001 2296 1126 Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN 46202 USA
4 https://ror.org/01zpmbk67 grid.280828.8 0000 0000 9681 3540 Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202 USA
5 https://ror.org/01kg8sb98 grid.257410.5 0000 0004 0413 3089 Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN 46202 USA
6 https://ror.org/02ets8c94 0000 0001 2296 1126 Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202 USA
7 https://ror.org/02ets8c94 0000 0001 2296 1126 Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202 USA
8 https://ror.org/02ets8c94 0000 0001 2296 1126 Department of Radiology & Imaging Sciences, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202 USA
18 1 2024
18 1 2024
2024
22 5 483494
21 12 2023
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose of Review

This comprehensive review discusses the complex relationship between Alzheimer’s disease (AD) and osteoporosis, two conditions that are prevalent in the aging population and result in adverse complications on quality of life. The purpose of this review is to succinctly elucidate the many commonalities between the two conditions, including shared pathways, inflammatory and oxidative mechanisms, and hormonal deficiencies.

Recent Findings

AD and osteoporosis share many aspects of their respective disease-defining pathophysiology. These commonalities include amyloid beta deposition, the Wnt/β-catenin signaling pathway, and estrogen deficiency. The shared mechanisms and risk factors associated with AD and osteoporosis result in a large percentage of patients that develop both diseases. Previous literature has established that the progression of AD increases the risk of sustaining a fracture. Recent findings demonstrate that the reverse may also be true, suggesting that a fracture early in the life course can predispose one to developing AD due to the activation of these shared mechanisms. The discovery of these commonalities further guides the development of novel therapeutics in which both conditions are targeted.

Summary

This detailed review delves into the commonalities between AD and osteoporosis to uncover the shared players that bring these two seemingly unrelated conditions together. The discussion throughout this review ultimately posits that the occurrence of fractures and the mechanism behind fracture healing can predispose one to developing AD later on in life, similar to how AD patients are at an increased risk of developing fractures. By focusing on the shared mechanisms between AD and osteoporosis, one can better understand the conditions individually and as a unit, thus informing therapeutic approaches and further research. This review article is part of a series of multiple manuscripts designed to determine the utility of using artificial intelligence for writing scientific reviews.

Keywords

Alzheimer’s disease
Osteoporosis
Wnt/β-catenin
Fracture healing
AI
Artificial intelligence
ChatGPT
http://dx.doi.org/10.13039/100000002 National Institutes of Health T35HL110854 AG078861/AG078861-S1 AG-064003 AG060621 U54AG054345 Wang Hannah S. Plotkin Lilian I. Movila Alexandru Kacena Melissa A. Oblak Adrian L. Richard L Roudebush VA Medical CenterI01BX005154 I01BX006399 Plotkin Lilian I. Kacena Melissa A. http://dx.doi.org/10.13039/100006975 Indiana Clinical and Translational Sciences Institute NIH UL1TR002529 Kacena Melissa A. issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

This is one of many articles evaluating the utility of using AI to write scientific review articles on musculoskeletal topics [1]. The first draft of this review was written entirely by humans. Refer to this edition’s Comment paper for more information [2]. Alzheimer’s disease and related dementias (AD/ADRD) and osteoporosis are two diseases that are prevalent in our aging population, and they unfortunately have a deleterious impact on quality of life [3]. Individuals living with AD typically experience a progressive loss of cognition, while those with osteoporosis are at increased risk of developing fractures. Patients diagnosed with both AD and osteoporosis may experience decreased cognitive agility, decreased mobility, and decreased ability to take care of themselves. Research has shown that these two disease processes are more intertwined than previously thought—in fact, they share many of the same molecular pathways and risk factors, such as old age, lifestyle, and fractures [4, 5]. While not the focus of this review, it is important to note that bone-brain cross-talk may be important in this process. Indeed, Yuan et al. recently reviewed the role of bone-derived modulators and AD progression. They describe that bone-derived cells and secreted proteins interact with multiple organ systems including the central nervous system, and such cross-talk between systems is important in the progression of AD [6]. In the current review, the commonalities between AD and osteoporosis will be elucidated, and a discussion of AD and fractures will seek to uncover whether each of the diseases affects the onset and progression of the other. Uncovering the complex relationship between these conditions could have important implications for improving prognosis and quality of life for those afflicted, which will be especially significant for our aging population.

Background on Alzheimer’s Disease and Related Dementias (AD/ADRD)

AD is the most common cause of dementia in the elderly and affects 6.7 million people in the USA, equaling roughly 1 in 9 individuals over the age of 65 [7]. Alzheimer’s disease and other dementias cost the USA $345B every year, with an additional estimated $339.5B in unpaid care, such as that provided by family and friends in the home [7]. AD is a deadly disease: deaths resulting from AD complications have doubled since 2000, and the 10-year survival rate for 70-year-old AD patients is half that of those without AD. AD is a multifactorial disease with many associated risk factors including advanced age, sex, genetic markers (e.g., apolipoproteinE4 (ApoE4) allele), traumatic head injuries, and environmental factors. Patients with AD present with multiple impairments including declines in cognition and memory and behavioral changes.

AD/ADRD is characterized by extracellular amyloid plaque deposition and intracellular neurofibrillary tangles in the medial temporal lobe of the brain, as well as widespread cerebral atrophy [8]. These pathological abnormalities result in many neurological changes in AD, which can be divided into two categories: positive lesions and negative lesions. Positive lesions are characterized by accumulations of abnormal deposits in the brain, such as amyloid plaques, and neurofibrillary tangles and negative lesions involve neuronal and synaptic loss. Abnormal deposition of beta-sheets has a strong correlation with dementia; beta-sheets provide the composition of fibrils, which aggregate to form amyloid plaques [9]. The transmembrane amyloid precursor protein (APP) is cleaved by proteolytic enzymes, yielding several varieties of amyloid beta (Aβ) monomers, including large and insoluble amyloid fibrils [10–12]. APP has been identified as a cause of early-onset AD when mutated [13]. The amyloid hypothesis posits that the degradation of the Aβ plaques is decreased with advanced age, thus leading to the aggregation of amyloid plaques. These amyloid plaques accumulate in chains of 39–43 amino acid Aβ peptides [14] throughout the brain causing neurotoxicity and inhibiting neural function, which can lead to cognitive impairment [8, 9, 12, 15]. Neurofibrillary tangles are hyperphosphorylated tau proteins and consist of accumulations of paired helical filaments that are characteristic of intracellular changes in AD [16]. Normally, tau acts as a scaffolding protein in microtubules to enrich axonal connections. Tau can undergo many post-translational modifications, such as monomethylation, acetylation, phosphorylation, and ubiquitination [17]. When tau protein becomes hyperphosphorylated, it begins to aggregate and loses its specificity for microtubules, impairing axonal function and causing neurodegeneration. The observed cerebral atrophy of negative lesions in AD is due to the loss of neurons and synapses throughout the brain, which may be more pronounced in the hippocampus and amygdala [8].

Despite the increasing prevalence of the disease, there is no cure for AD. Although the few drugs that have been approved by the FDA for AD are useful in temporarily alleviating symptoms, there has been little success in slowing or halting the progression of AD [17]. In July 2023, a new FDA-approved drug, lecanemab, showed a modest slowing of AD progression and reduced Aβ; however, debate is ongoing over the benefits in light of the undesirable side effects such as infusion-related reactions [18•].

Background on Osteoporosis

Osteoporosis is a prevalent skeletal condition associated with bone fragility due to low bone mass and compromised bone structure. It is estimated that there are over 10 million individuals living with osteoporosis in the USA [19]. The disruption of bone architecture seen in osteoporosis is a result of greater rates of bone loss than bone formation, which reduces bone strength and leads to an increased risk of fractures [20]. Bone remodeling is a continuous process of replacing older bone material with new bone material, helping to repair microfractures and preventing the onset of macrofractures. However, this process becomes impaired with aging-induced increases in bone resorption and reductions in bone formation. With this impaired balance, the architectural structure of bone becomes weakened due, in part, to a significantly reduced mass combined with deleterious changes in bone structure such as cortical thinning, leading to an increased incidence of fractures and subsequent decline in daily functioning.

Osteoporosis typically goes undiagnosed until a fracture occurs. A fracture of the hip or vertebrae without any severe trauma is diagnostic of the disease. Osteoporosis can also be diagnosed using a metric known as the T-score. This scoring involves measuring the patient’s bone mineral density (BMD) with a dual X-ray absorptiometry (DXA) scan and comparing this measurement to the mean BMD of young healthy people aged 20–29. BMD accounts for 70% of bone strength, with an additional 20% coming from bone quality, which is currently unmeasurable [20].

Overview of Alzheimer’s and Osteoporosis

While AD and osteoporosis seemingly affect very different organ systems, there are many commonalities between them. In fact, multiple AD mouse models have been shown to express an osteoporotic phenotype [21••]. In the current section, we will look at the underlying risk factors and pathways shared by AD and osteoporosis. It has been observed that osteoporosis and bone fracture occur at roughly twice the rate in AD patients compared to non-AD patients of comparable age [22]. Indeed, a previous cross-sectional study reported that individuals with AD were more likely to have sustained a hip fracture during their lifetime, have concurrent osteoporosis, and have fallen, as compared to individuals with no diagnosis of AD [23]. The risk factors between AD and osteoporosis that are shared include advanced age of the patients, poor nutrition, poor gait, impaired metabolism due to underlying co-morbidities, and sex-based differences in physiology.

Aβ has been implicated in the damage of bone tissue, as it has been shown that Aβ directly interacts with bone cells to increase bone resorption by osteoclasts and inhibit differentiation of osteoblasts, thus compromising bone architecture. APP, a transmembrane protein mentioned earlier as a precursor to amyloid plaques in the brain, is also expressed in osteoblasts and osteoclasts, two cell types important for bone remodeling. When certain mutations in APP occur, osteoblast differentiation is suppressed, preventing new bone growth and laying the foundation for osteoporosis [13].

Many pathways have been identified as having commonalities in both AD and osteoporosis. Studies have shown that patients with osteoporosis have an increased risk of developing AD compared to those without osteoporosis [24]. Furthermore, osteoporosis typically precedes a diagnosis of AD. This could indicate a pathophysiological link, which is not yet well understood.

While many observational studies have established an association between AD and osteoporosis, a recent two-sample Mendelian randomization study found that there was no distinct causal genetic link between the two conditions [25]. These researchers isolated potentially pleiotropic single nucleotide polymorphisms and found that the removal of such genes did not confer the development of osteoporosis or AD directly. It is worth mentioning that in addition to genetic links, environmental and physiological causes can be determinants of diseases, especially diseases associated with aging. As mentioned earlier and discussed in detail in the sections to follow, AD and osteoporosis share similar pathways and pathogenesis, which continue to require further investigation.

Shared Pathways Between Alzheimer’s Disease and Osteoporosis

The Wnt/β-catenin signal transduction pathway regulates many cellular processes in the body, including cell survival [26]. In the brain, this pathway works to increase neuronal survival, promote neurogenesis, and regulate synaptic plasticity [26]. The Wnt/β-catenin signaling pathway has been linked to AD, as its normal activation serves to inhibit Aβ production and tau phosphorylation (p-tau) in the brain. In aging brains, Wnt/β-catenin signaling is downregulated, and this suppression is even greater in AD brains [27]. Loss of function of the Wnt co-receptor LRP6 has been shown to downregulate the Wnt/β-catenin signaling pathway and is associated with an increased risk of developing AD [28, 29] while contributing to the synaptic dysfunction and Aβ accumulation seen in AD [30].

The Wnt/β-catenin signaling pathway is also a critical player in the facilitation of bone formation. The loss of Wnt/β-catenin signaling in osteocytes, specifically β-catenin gene deletion, causes an elevation of both the number and activity of osteoclasts, leading to substantial bone loss [31]. Furthermore, osteoclasts stimulate osteoblast differentiation through the secretion of Wnt ligands and chemoattractants to aid in skeletal remodeling [32]. Osteoblastic cells in turn impact osteoclastogenesis through the expression of RANKL and OPG, which work to differentiate osteoclasts [33, 34]. Thus, the interplay between bone regeneration and remodeling involves cytokine signaling, including Wnt/β-catenin, RANKL, and OPG which at least the former has also been implicated in AD as described in more detail below.

Studies using mouse models of AD, rat neurons in vitro cultures, and samples from human Alzheimer’s patients have identified deficits in the Wnt/β-catenin signaling pathway that accounts for both the Aβ and tau pathogenesis seen in AD, as well as the characteristic bone loss of osteoporosis. The Wnt/β-catenin signaling pathway has been shown to facilitate bone formation and promote synapse formation in the brain [22], and the disruption of this pathway has been implicated in both the onset of osteoporosis and AD. In relation to AD, the inhibition of the pathway allows for the unregulated production of p-tau and Aβ, leading to the accumulation and deposition of these proteins [22, 35]. Upon accumulation of p-tau and Aβ, inflammatory pathways are activated, further inhibiting the Wnt/β-catenin signaling pathway and contributing to a vicious cycle of p-tau and Aβ deposition. Disruptions in Wnt/β-catenin signaling are typically seen prior to the onset of AD [22, 36]. Dengler-Crish and Elefteriou in 2019 hypothesized that a disruption in the Wnt/β-catenin signaling pathway causes peripheral accumulation of Aβ initially and that the positive-feedback loop of further accumulation leads to deposition in the central nervous system, contributing to the pathogenesis of AD [22].

Angiogenesis

Angiogenesis is the process of forming new blood vessels from existing vasculature [37]. Angiogenesis is vital for proper bone repair, as it is involved in the development of new bone tissue and bone remodeling [38–41]. Angiogenesis is also a highly relevant process in AD, as the accumulation of amyloid plaques damages the cerebrovasculature.

A study using a transgenic mouse model (Tg APPsw) of amyloidosis found that the overexpression of APP may oppose angiogenesis, leading to decreased functional vasculature in the brain [14]. The impaired angiogenesis seen in AD patients leads to decreased capillary diameter, thinning of the capillary basement membrane, and atrophy of the cerebrovascular smooth muscle [14, 42–44]. Furthermore, Aβ peptides are also powerful inhibitors of angiogenesis, in both in vitro and in vivo studies [45]. The capillary network in cerebral cortices has demonstrated severe amyloid plaque accumulation and deposition, compromising the cerebrovasculature with a loss of small cortical arterioles and capillaries [14, 46]. Previous studies have shown that AD patients have increased levels of VEGF in the brain, a potent angiogenic factor necessary for the growth of vascular endothelial cells. This increase of VEGF suggests a compensatory mechanism in response to damaged cerebral structure, even though this mechanism ultimately fails to yield proper angiogenesis [14, 47, 48].

Bone repair following fracture constitutes an interplay between angiogenic and osteogenic pathways. Angiogenesis is necessary for fracture healing to occur and to prevent the onset of osteoporosis. Angiogenesis in actively regenerating calluses supplies the nutrients, oxygen, cytokines, and growth factors necessary for the formation of osteoblasts and osteoclasts, ultimately leading to bone formation [49]. Studies have shown that disruption in angiogenesis precedes the onset of osteoporosis, as inadequate blood flow is linked to impaired bone remodeling and subsequent low bone mass [40]. By a similar mechanism, angiogenesis also precedes osteogenesis. The endothelial cells are arguably the most important components of the vasculature, as they maintain a permeable barrier and allow for the recruitment of hematopoietic cells to the bone site to maintain bone homeostasis and facilitate fracture repair [40, 50–52].

Bone Mineral Density (BMD)

Lower BMD is associated with an increased risk of developing AD [53]. On the other hand, studies have shown that AD patients have reduced hip BMD and are at twice the risk of developing hip fractures [54, 55]. Large prospective studies have demonstrated an association between reduced BMD and an increased incidence of AD in the elderly [5, 53, 56–58]. Supporting this idea, a recent meta-analysis of three longitudinal studies found that a higher baseline BMD has a significant protective association with incident dementia (new cases of dementia); however, prior bone loss was not found to be associated with incident dementia [59].

A study in a Chinese population examined the potential role of low BMD on the transition from mild cognitive impairment to AD and found a positive relationship between osteoporosis and the decline in cognitive function observed in AD. Subjects in the lowest quartile for BMD were at twice the risk for AD compared to controls. Furthermore, the study revealed that individuals who were identified to have mild cognitive impairment at study onset were more likely to develop AD if they had a low baseline BMD. The study also showed that severe low BMD at baseline was associated with an increased risk of developing AD; this association was seen in both men and women [57]. Together, these studies imply a link between bone density loss and Alzheimer’s that requires exploration of common risk factors to identify a potential root cause.

The Protective Effect of Estrogen

Dementias have a variety of risk factors, including sex. Depending on the type of dementia, the epidemiology of male-to-female prevalence varies. AD is the most common form of dementia, with females constituting roughly 2/3 of all affected individuals [60]. The increased prevalence of AD in females as compared to men is likely due to the loss of the protective effect of estrogen in females with menopause. Indeed, in the normal brain, estrogen works in the nucleus basalis of Meynert to maintain normal cognitive function [61]. Furthermore, a cross-sectional study conducted in the Netherlands reported that women in the highest quintile of estradiol or estrone were 40% less likely to experience cognitive impairment compared to those in the lowest quintile [62], suggesting a protective effect of estrogen. Studies indicate that estrogen deprivation plays a vital role in the onset of cognitive decline and increased risk for AD in both men and women [61].

A study by Hoskin et al. found that levels of sex hormone–binding globulin (SHBG) were 20% higher in AD patients and that levels of estradiol were significantly reduced, compared to controls [63]. An estimated 37% of estradiol in elderly women circulates in the body bound to SHBG, the form that is postulated to be unable to cross the blood–brain barrier and thus cannot exert effects on the CNS. In other words, roughly 37% of elderly women’s estradiol is unable to be used for the protective effect of estrogen on the brain. Similarly, several observational studies have found an association between increased levels of SHBG and AD [61, 64, 65].

While these studies are promising for elucidating the negative effects of low estrogen levels on increased risk of developing AD in elderly women, there are conflicting studies that suggest a lack of association. The Rancho Bernardo study did not find a significant effect on cognitive test outcome due to bioavailable estradiol [66], and the Rotterdam study found that women with greater bioavailable estradiol levels demonstrated significantly poorer cognitive function [67]. However, these conflicting results may be due to variations in hormone measurement procedures [61].

Estrogen receptors are heavily expressed in osteoblasts, osteoclasts, and osteocytes, making their interaction with estrogen an important factor in the success of bone remodeling throughout the lifetime. Osteoporosis in post-menopausal women is directly related to estrogen deficiency. A deficiency in estrogen leads to increased bone resorption and a negative balance between bone resorption and formation [68]. Estrogen binds to estrogen receptors to inhibit osteoclast formation via the expression of osteoprotegerin. Estrogen can also activate the Wnt/β-catenin signaling pathway to increase osteogenesis. Thus, a lack of estrogen will alter the expression of target genes such as interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha (TNFα), insulin-like growth factor (IGF), and transforming growth factor beta (TGFβ), decreasing osteogenesis. In females, the primary treatment for estrogen deficiency–related osteoporosis is estrogen supplements [68], primarily in the form of transdermal estradiol [69].

When estrogen binds to its receptors, it can also regulate the expression of gene-encoding proteins such as IL-1, IGF, and TGFβ [70]. Estrogen works to upregulate bone morphogenetic protein (BMP) signaling, which promotes mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts, enhancing bone formation in the remodeling process [68]. Estrogen also suppresses the action of receptor activator of nuclear factor kβ ligand (RANKL) to inhibit osteoclast activity. RANK is expressed on osteoclast precursors, and binding by RANKL promotes osteoclast formation and subsequent resorption. When estrogen binds to osteoclast-expressed estrogen receptors, RANK activity is suppressed [71]. Furthermore, estrogen inhibits the differentiation of osteoclasts and promotes osteoclast apoptosis through the increase of TGFβ production. Thus, estrogen serves to regulate the bone resorption rate.

Osteocytes are the foundational bone material and serve to control bone remodeling and mineralization [68]. The decline in estrogen levels in menopausal women has been associated with bone loss [72, 73] characterized by an increase in both osteoblasts and osteoclasts [74]. In men, low androgen levels result in bone loss and increased bone remodeling [75, 76], in part due to lower levels of estrogen [77]. A study found that in the absence of estrogen receptors, osteocytes were not able to provide an adequate response to received mechanical strain, thus representing a deficiency of osteocyte mechanosensory ability in the absence of estrogen [78].

Estrogen deficiency has major contributions to the pathophysiology of both AD and osteoporosis, affecting both the risk and progression of both diseases. While there has been some conflicting evidence about the role of estrogen in AD, it is reasonable to identify the deficiency of this hormone as a common risk factor between the two conditions, and estrogen may play a role in a shared disease mechanism. Identifying and unraveling the complex relationship between sex hormones and AD progression as well as the shared commonalities of pathways in bone disorders may help in developing potential therapies to improve bone mass while slowing the progression of AD, especially in post-menopausal women.

Benefits of FSH Blockade

Follicle-stimulating hormone (FSH) is an important regulator in the reproductive systems of men and women, and its blockade is shown to have beneficial effects on inhibiting the hallmarks of AD such as Aβ deposition and p-tau [79••]. Previous studies in mice have shown that FSH works to increase bone mass and enhance thermogenesis, two factors which are dysregulated in AD [80–82]. A study by Xiong et al. demonstrates that FSH accelerates Aβ and tau deposition in the hippocampus and cortical neurons, thus impairing cognition in 3xTg-AD mice. The study shows that blocking the action of FSH in 3xTg-AD mice inhibits the formation of plaque and neurofibrillary tangles, thus alleviating these adverse cognitive symptoms [79••]. Furthermore, recent results indicate that anti-FSH antibody is useful in increasing the bone formation of the femur and spine in mice [83•].

Neuroinflammation

Current evidence suggests that the progression and severity of AD can be attributed to the immunological mechanisms that occur in the brain [84]. For example, expression of immune receptors, such as triggering receptor expressed on myeloid cells 2 (TREM2) [85] and CD33 [86, 87], has been found to be associated with AD, suggesting that neuroinflammation contributes to the onset and progression of AD [84]. TREM2 is expressed in the microglia of the brain, and the variant R47H has been found to present a significantly higher risk of late-onset AD development [88]. Furthermore, the TREM2 variant Y38C in the brain disrupts the normal functionality of TREM2, causing changes in the microglia morphology and impairing the synaptic plasticity in the hippocampus. The downstream effects of the dysfunction of TREM2 provide an explanation of the events leading to AD and dementia [88]. These downstream effects are discussed in detail by Lee-Gosselin et al., who found in the brains of TREM2−/− mice injected with human tau extract that there was a significant decrease in microglial density compared to controls, as well as diminished tau pathology. This suggests that the experimental mice may not demonstrate a sufficient activated inflammatory response in the presence of tau pathologies, such as aggregation [89]. The observations from Lee-Gosselin et al. suggest that deletion of TREM2 may be beneficial in improving certain hallmarks of AD.

Additionally, it is hypothesized that the formation of neurofibrillary tangles is due to the neurotoxicity seen in neuroinflammation [16]. Furthermore, activated microglia and astrocytes seen in the inflammatory process surround the amyloid plaque depositions, resulting in higher levels of inflammatory mediators than observed in non-AD brains [90]. Reactive astrogliosis has been shown to occur in many neurodegenerative tauopathies, such as AD [91]. Taken together, these observations implicate neuroinflammation and the glial response as contributors to the damage of neurons and ultimately AD [92, 93].

Limited work has been conducted looking at the link between neuroinflammation and bone. TREM2 is expressed on osteoclasts, regulating the rate of osteoclastogenesis, and a study by Otero et al. reports that TREM2−/− mice exhibit osteopenic phenotype resembling the Nasu-Hakola disease [94, 95]. Furthermore, the TREM2 R47H variant has been implicated in low bone mass and skeletal muscle strength seen in TREM2R47H/+ mutant female mice, independent of central nervous system pathology [96].

Oxidative Stress

Reactive oxygen species (ROS) are free radicals that regulate cellular homeostasis and can be formed from both endogenous and exogenous sources. Endogenous sources of ROS include the mitochondrial respiratory chain and various enzymatic reactions, while exogenous sources are various stressors such as ionizing radiation and oxidizing chemicals [97]. Normally, ROS are important messengers in cell signaling, but at high concentrations, they can cause damage to cells leading to necrosis and apoptosis [97].

Oxidative stress is a major contributor to the progression of AD [97], with ROS being a critical player in the pathology of AD [98]. Oxidative stress has been shown to expedite aging and accelerate the onset of AD. The progressive cell loss due to oxidative stress can lead to the onset of neurodegenerative diseases; in AD, this causes abnormal aggregation of amyloid proteins [97]. In patients with AD, there is significant oxidative damage to brain tissue [99, 100], which leads to the upregulation of Aβ and p-tau formation [97, 99]. Double bond peroxidation in polyunsaturated neuronal lipid products forms molecules that stimulate p-tau [98, 101–105].

Oxidative stress has also been implicated as a causative factor in the diminished BMD in osteoporosis [106]. Kimball et al. cite four avenues through which oxidative stress affects the pathway of bone metabolism: (1) upregulation of osteoclastogenesis, (2) decreased osteoprogenitor differentiation, (3) decreased osteoblast activity, and (4) increased osteoblast and osteocyte apoptosis [106]. Oxidative stress causes increased osteoclastogenesis through the upregulation of RANKL and downregulation of osteoprotegerin; these two factors are an osteoclast activator and inhibitor, respectively [107–109], and occur via the Wnt/β-catenin pathway [107]. A study has shown that hydrogen peroxide–induced oxidative stress decreases osteoblast differentiation, thus inhibiting the formation of new bone [110]. Decreased osteoblast differentiation leads to decreased osteoblast activity and thus decreased osteoprotegrin production [106], ultimately ceasing regulation of osteoclast activity. Osteoblast and osteocyte apoptosis increase with oxidative stress, further inhibiting osteogenesis [106], while stimulating osteoclastogenesis via decreased osteoblastic cytokine activity [33, 111–115].

Therapies

There are currently three classes of FDA-approved drugs to treat AD: cholinesterase inhibitors, NMDA antagonists [8], and monoclonal antibodies. Acetylcholinesterase inhibitors function to block the breakdown of acetylcholine, thereby increasing the levels of acetylcholine in the synaptic cleft [116–118]. This medication helps to reduce the effects of the reduced cholinergic transmission throughout the brain due to the destruction of acetylcholine-producing cells in AD [8]. NMDA antagonists work to prevent cell death and synaptic dysfunction caused by excitotoxic overactivation of the NMDA receptor and subsequent increased levels of calcium [119, 120]. These two drugs are effective in managing the symptoms of AD but do not cure the disease [8, 17]. Due to the lack of disease-modifying therapies, research has focused on prevention or risk reduction of AD [121]. Studies have shown that lifestyle modifications such as physical activity, diet, and cognitive training can increase or maintain cognitive function and reduce new cases of AD in the elderly [8, 122]. Monoclonal antibodies have shown some promise in slowing the progression of AD. Trials using the monoclonal antibody aducanumab reported that high doses of the drug had the potential to slow the cognitive decline seen in AD, and the drug was given conditional FDA approval in 2022 [123]. Lecanemab, a humanized IgG1 monoclonal antibody [18•] which received FDA approval in July 2023, was found to reduce the markers of amyloid plaques in early-onset AD and led to less cognitive decline after 18 months of use, when compared to placebo. While this is the first drug that demonstrates slowing of AD progression to receive full FDA approval, ongoing studies are being conducted to determine the overall safety of the drug [18•].

In contrast, lifestyle modifications are the first-line treatment for the prevention or treatment of osteoporosis [124]. These modifications include eating a healthy and varied diet with calcium-rich and vitamin-rich foods [125], as well as reducing alcohol consumption and avoiding smoking [126]. However, these lifestyle modifications may not be enough for some patients, and thus, there are a variety of pharmaceutical options. There are two main treatment categories: anabolic treatments, which activate osteoblasts [127], and inhibitors of catabolism, which inhibit osteoclast-mediated resorption [128]. The most commonly prescribed anabolic treatments are parathyroid hormone (PTH) derivatives [124], although few patients receive full-length PTH and administration of PTH derivatives is given intermittently. PTH is a hormone known to promote bone resorption when administered continuously and promote bone regeneration when administered intermittently, regulating endochondral bone development [124], while maintaining higher BMD [129]. The most prescribed anti-catabolic treatments for osteoporosis are bisphosphonates. Bisphosphonates inhibit osteoclast activity and induce osteoclast apoptosis, thereby blocking bone resorption and stopping bone loss [124]. Thus, these two treatment categories serve to target osteoporotic pathologies at the mechanistic level to slow progression.

Increased Risk of Fractures Following Alzheimer’s Disease Diagnosis

It is well known that fracture is the most common sequela of osteoporosis, but it has been found to be a complication in AD as well. Research has shown that individuals with AD are more than twice as likely to sustain fractures at disease onset, despite having comparable risk to controls prior to the onset of AD symptoms [130•]. This increased risk occurs as soon as the first year of disease onset [131, 132]. The main risk factors for the increased incidence of hip fractures in AD patients are low BMD [4, 133], low concentrations of serum ionized calcium, and low concentrations of 25-hydroxyvitamin with compensatory hyperparathyroidism [134, 135]. Following a hip fracture, functional recovery is poor in AD patients [134, 136, 137], with individuals having a significantly lower ambulatory level [138] and greater risk of immobilization [139] compared to controls. Furthermore, AD patients have a higher risk of post-fracture mortality [140]. Another study found that individuals with dementia were at an even higher risk of developing a hip fracture if they also had diagnosed osteoporosis [54]. This idea is supported by the fact that individuals with AD have an increased risk of falling and subsequent fracture, with co-occurring osteoporosis being one of the strongest predictors of hip fractures [4, 54, 141, 142].

Increased Risk of Developing Dementia/AD Following Fracture Incidence

A 2020 observational study found that an incidence of distal radius, hip, and spine fractures increased the risk of developing dementia in individuals greater than 60 years of age [143]. A retrospective study found that, after a 12-year follow-up period, the overall incidence rate of dementia following fracture was 41% higher than in individuals who did not experience a fracture incidence [3]. Interestingly, the degree of increased risk varies depending on the fracture site, with hip fractures being the greatest at 60% higher risk of developing dementia. Comparatively, those with vertebral fractures had a 47% higher risk, those with thigh/leg/ankle fractures had a 35% higher risk, and those with an upper limb fracture exhibited a 29% increased risk [3].

There are several factors, both during the fracture incidence and healing process, that have been proposed to predispose or increase the risk of one developing dementia. It is hypothesized that fractures can predispose individuals to developing dementia due to the inflammatory process and reactive oxidative stress associated with fracture healing [143], as well as impaired balance [144–146] and vestibular asymmetry [147–149]. Following a fracture incidence, the inflammatory cytokines TNFα and IL-6 are elevated [150] in both the cerebrospinal fluid and peripheral blood [151, 152], and these two factors have been implicated in dementia [153]. Furthermore, ROS levels increase during fracture healing [154], which may lead to oxidative brain injury, thus increasing the risk of dementia [155].

Following a fracture, the complications of recovery may increase the risk of dementia via decreased physical activity and postoperative delirium [143]. Observed functional mobility declined in patients following a fracture [156], and a retrospective study found that roughly 32% of hip fracture patients who experienced postoperative delirium were later diagnosed with dementia [157].

Even though there are some observational clinical studies showing an association between the incidence of fractures and an increased risk of AD, to date, no studies exist in either humans or animal models of AD showing a link between fractures and AD progression. Due to a lack of these studies, it is imperative that this less understood link be explored further to uncover the intertwined pathways between fractures, bone health, inflammation, and AD.

Conclusion

As illustrated in Fig. 1, Alzheimer’s disease and osteoporosis share many of the same disease mechanisms, such as altered angiogenesis, low BMD, a decrease in estrogen levels, neuroinflammation, and increased oxidative stress. The diseases both involve some of the same signaling pathways, and some of the characteristic molecular hallmarks of AD, such as Aβ and APP, have been shown to play a role in osteoporosis as well. One disease often predisposes an individual to the other, and many elderly patients concurrently have both AD and osteoporosis. The co-occurrence of these two degenerative diseases provides a great negative impact on the individual, namely, an increase in fractures and subsequent decreased mobility. Fractures have been shown to occur at greater rates in AD and osteoporosis patients compared to controls, largely due to the low BMD seen in both diseases. Interestingly, recent evidence suggests that an incidence of fracture also predisposes one to developing dementia, suggesting further commonalities between these two common geriatric diseases. Further exploration on fracture incidence causing AD onset is warranted, as this could uncover additional mechanistic commonalities and provide more insight into the pathogenesis of AD. Osteoporosis, AD, and fracture are debilitating ailments with recently uncovered similarities in pathophysiology. It is important to note that mouse models exploring such links have a variety of limitations, largely due to incomplete replication of the remodeling patterns seen in humans. As a result, there is a need for more human studies. That said, a limitation of human studies is the difficulty of drawing inferences related to pathways and mechanisms involved. Thus, both preclinical and clinical studies are essential to tackle these debilitating diseases. Finally, understanding the complex relationship between osteoporosis, AD, and fracture healing will be crucial to the development of therapies to improve the lives of people everywhere, especially the elderly.Fig. 1 Alzheimer’s disease and osteoporosis share many commonalities in their disease processes, such as inflammation, oxidative stress, estrogen deficiency, and, therefore, potential for shared therapeutics

Author Contributions

This review article was conceived by MAK, JCF, LIP, AM, and ALO. HSW performed the initial literature search and wrote the first draft of the manuscript. All authors revised the manuscript critically for important intellectual content, take responsibility for all aspects of the work, and approve of the final version of the manuscript.

Funding

The funding for these studies was provided in part by the NIH (AG060621-05S1/-05S2 (MAK), U54AG054345 (ALO), AG078861/AG078861-S1 (LIP), AG-064003 (AM), K02AG-068595 (AM), and T35HL110854 (HSW)). This work was also supported in part by the Indiana University School of Medicine, the Indiana Clinical and Translational Sciences Institute (funded in part by NIH UM1TR004402), the Indiana Center for Musculoskeletal Health, the Stark Neuroscience Research Institute, and the Department of Orthopaedic Surgery. This material is also the result of work supported with resources and the use of facilities at the Richard L. Roudebush VA Medical Center, Indianapolis, IN: VA Merit I01BX006399 (MAK) and I01RX003552 (MAK) and I01BX005154 (LIP). The presented contents are solely the responsibility of the authors and do not necessarily represent the official views of any of the aforementioned agencies.

Declarations

Competing interests

Dr. Kacena is Editor-in-Chief for Current Osteoporosis Reports. Drs. Fehrenbacher and Plotkin are Section Editors for Current Osteoporosis Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. Kacena MA, Plotkin LI, Fehrenbacher JC. The use of artificial intelligence in writing scientific review articles. Curr Osteoporos Rep. 2024. 10.1007/s11914-023-00852-0.
2. Margetts TJ, Karnik SJ, Wang HS, et al. Use of AI language engine ChatGPT 4.0 to write a scientific review article examining the intersection of alzheimer’s disease and bone. Curr Osteoporos Rep. 2024. 10.1007/s11914-023-00853-z.
3. Tsai CH Fracture as an independent risk factor of dementia: a nationwide population-based cohort study Medicine (Baltimore) 2014 93 26 e188 25474435
Tsai CH, et al. Fracture as an independent risk factor of dementia: a nationwide population-based cohort study. Medicine (Baltimore). 2014;93(26): e188.25474435
4. Friedman SM Dementia and hip fractures: development of a pathogenic framework for understanding and studying risk Geriatr Orthop Surg Rehabil 2010 1 2 52 62 23569663
Friedman SM, et al. Dementia and hip fractures: development of a pathogenic framework for understanding and studying risk. Geriatr Orthop Surg Rehabil. 2010;1(2):52–62.23569663
5. Lui LY Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures J Am Geriatr Soc 2003 51 1 38 43 12534843
Lui LY, et al. Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc. 2003;51(1):38–43.12534843
6. Yuan J The potential influence of bone-derived modulators on the progression of Alzheimer’s disease J Alzheimers Dis 2019 69 1 59 70 30932886
Yuan J, et al. The potential influence of bone-derived modulators on the progression of Alzheimer’s disease. J Alzheimers Dis. 2019;69(1):59–70.30932886
7. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19(4):1598–695. 10.1002/alz.13016.
8. Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789. 10.3390/molecules25245789.
9. Chen GF Amyloid beta: structure, biology and structure-based therapeutic development Acta Pharmacol Sin 2017 38 9 1205 1235 28713158
Chen GF, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205–35.28713158
10. Cras P Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein Proc Natl Acad Sci U S A 1991 88 17 7552 7556 1652752
Cras P, et al. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991;88(17):7552–6.1652752
11. Perl DP Neuropathology of Alzheimer’s disease Mt Sinai J Med 2010 77 1 32 42 20101720
Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):32–42.20101720
12. Armstrong RA The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease Folia Neuropathol 2009 47 4 289 299 20054780
Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009;47(4):289–99.20054780
13. Xia WF Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine J Bone Miner Res 2013 28 10 2122 2135 23649480
Xia WF, et al. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013;28(10):2122–35.23649480
14. Paris D Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis Neurosci Lett 2004 366 1 80 85 15265595
Paris D, et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett. 2004;366(1):80–5.15265595
15. Tabaton M Piccini A Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer’s disease Int J Exp Pathol 2005 86 3 139 145 15910548
Tabaton M, Piccini A. Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer’s disease. Int J Exp Pathol. 2005;86(3):139–45.15910548
16. Metcalfe MJ Figueiredo-Pereira ME Relationship between tau pathology and neuroinflammation in Alzheimer’s disease Mt Sinai J Med 2010 77 1 50 58 20101714
Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):50–8.20101714
17. Du X Wang X Geng M Alzheimer’s disease hypothesis and related therapies Transl Neurodegener 2018 7 2 29423193
Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Transl Neurodegener. 2018;7:2.29423193
18. • van Dyck CH, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. This study reported a reduction in cognitive and functional decline in AD patients treated with lecanemab, a new monoclonal antibody that targets amyloid beta-soluble protofibrils.
19. Sarafrazi N Wambogo EA Shepherd JA Osteoporosis or low bone mass in older adults: United States, 2017–2018 NCHS Data Brief 2021 405 1 8
Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017–2018. NCHS Data Brief. 2021;405:1–8.
20. Sozen T Ozisik L Basaran NC An overview and management of osteoporosis Eur J Rheumatol 2017 4 1 46 56 28293453
Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.28293453
21. •• JE LL, et al. Degradation of bone quality in a transgenic mouse model of Alzheimer’s disease. J Bone Miner Res. 2022;37(12):2548–65. 10.1002/jbmr.4723. This primary research study utilized a 5xFAD transgenic model of AD to establish a relationship between elevated Aβ levels and impairment of bone health in mice.
22. Dengler-Crish CM Elefteriou F Shared mechanisms: osteoporosis and Alzheimer’s disease? Aging (Albany NY) 2019 11 5 1317 1318 30779704
Dengler-Crish CM, Elefteriou F. Shared mechanisms: osteoporosis and Alzheimer’s disease? Aging (Albany NY). 2019;11(5):1317–8.30779704
23. Weller II The relation between hip fracture and Alzheimer’s disease in the canadian national population health survey health institutions data, 1994–1995 A cross-sectional study Ann Epidemiol 2000 10 7 461 11018377
Weller II. The relation between hip fracture and Alzheimer’s disease in the canadian national population health survey health institutions data, 1994–1995 A cross-sectional study. Ann Epidemiol. 2000;10(7):461.11018377
24. Chen YH Lo RY Alzheimer’s disease and osteoporosis Ci Ji Yi Xue Za Zhi 2017 29 3 138 142 28974906
Chen YH, Lo RY. Alzheimer’s disease and osteoporosis. Ci Ji Yi Xue Za Zhi. 2017;29(3):138–42.28974906
25. Hu H No genetic causal association between Alzheimer’s disease and osteoporosis: a bidirectional two-sample Mendelian randomization study Front Aging Neurosci 2023 15 1090223 36761181
Hu H, et al. No genetic causal association between Alzheimer’s disease and osteoporosis: a bidirectional two-sample Mendelian randomization study. Front Aging Neurosci. 2023;15:1090223.36761181
26. Jia L Pina-Crespo J Li Y Restoring Wnt/beta-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease Mol Brain 2019 12 1 104 31801553
Jia L, Pina-Crespo J, Li Y. Restoring Wnt/beta-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease. Mol Brain. 2019;12(1):104.31801553
27. Garcia-Velazquez L Arias C The emerging role of Wnt signaling dysregulation in the understanding and modification of age-associated diseases Ageing Res Rev 2017 37 135 145 28624530
Garcia-Velazquez L, Arias C. The emerging role of Wnt signaling dysregulation in the understanding and modification of age-associated diseases. Ageing Res Rev. 2017;37:135–45.28624530
28. De Ferrari GV Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease Proc Natl Acad Sci U S A 2007 104 22 9434 9439 17517621
De Ferrari GV, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease. Proc Natl Acad Sci U S A. 2007;104(22):9434–9.17517621
29. Alarcon MA A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer’s disease Neurobiol Aging 2013 34 6 1709.e9 18 23218566
Alarcon MA, et al. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer’s disease. Neurobiol Aging. 2013;34(6):1709.e9-18.23218566
30. Liu CC Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease Neuron 2014 84 1 63 77 25242217
Liu CC, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease. Neuron. 2014;84(1):63–77.25242217
31. Kramer I Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis Mol Cell Biol 2010 30 12 3071 3085 20404086
Kramer I, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30(12):3071–85.20404086
32. Pederson L Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate Proc Natl Acad Sci U S A 2008 105 52 20764 20769 19075223
Pederson L, et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008;105(52):20764–9.19075223
33. Henriksen K Local communication on and within bone controls bone remodeling Bone 2009 44 6 1026 1033 19345750
Henriksen K, et al. Local communication on and within bone controls bone remodeling. Bone. 2009;44(6):1026–33.19345750
34. Martin T Gooi JH Sims NA Molecular mechanisms in coupling of bone formation to resorption Crit Rev Eukaryot Gene Expr 2009 19 1 73 88 19191758
Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009;19(1):73–88.19191758
35. Inestrosa NC Varela-Nallar L Wnt signaling in the nervous system and in Alzheimer’s disease J Mol Cell Biol 2014 6 1 64 74 24549157
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol. 2014;6(1):64–74.24549157
36. Dengler-Crish CM Evidence of Wnt/beta-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer’s disease Neurobiol Aging 2018 67 148 158 29660685
Dengler-Crish CM, et al. Evidence of Wnt/beta-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer’s disease. Neurobiol Aging. 2018;67:148–58.29660685
37. Adair TH, Montani JP. Angiogenesis. San Rafael (CA). Integrated Systems Physiology: from Molecule to Function to Disease. 2010. 10.4199/C00017ED1V01Y201009ISP009.
38. Colnot CI Helms JA A molecular analysis of matrix remodeling and angiogenesis during long bone development Mech Dev 2001 100 2 245 250 11165481
Colnot CI, Helms JA. A molecular analysis of matrix remodeling and angiogenesis during long bone development. Mech Dev. 2001;100(2):245–50.11165481
39. Gerstenfeld LC Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation J Cell Biochem 2003 88 5 873 884 12616527
Gerstenfeld LC, et al. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem. 2003;88(5):873–84.12616527
40. Saran U Gemini Piperni S Chatterjee S Role of angiogenesis in bone repair Arch Biochem Biophys 2014 561 109 17 25034215
Saran U, Gemini Piperni S, Chatterjee S. Role of angiogenesis in bone repair. Arch Biochem Biophys. 2014;561:109–17.25034215
41. Bhatti FUR The effects of high fat diet, bone healing, and BMP-2 treatment on endothelial cell growth and function Bone 2021 146 115883 33581374
Bhatti FUR, et al. The effects of high fat diet, bone healing, and BMP-2 treatment on endothelial cell growth and function. Bone. 2021;146:115883.33581374
42. Claudio L Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer’s disease patients Acta Neuropathol 1996 91 1 6 14 8773140
Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer’s disease patients. Acta Neuropathol. 1996;91(1):6–14.8773140
43. Kalaria RN Hedera P Differential degeneration of the cerebral microvasculature in Alzheimer’s disease NeuroReport 1995 6 3 477 480 7766847
Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer’s disease. NeuroReport. 1995;6(3):477–80.7766847
44. Mancardi GL Thickening of the basement membrane of cortical capillaries in Alzheimer’s disease Acta Neuropathol 1980 49 1 79 83 7355675
Mancardi GL, et al. Thickening of the basement membrane of cortical capillaries in Alzheimer’s disease. Acta Neuropathol. 1980;49(1):79–83.7355675
45. Paris D Inhibition of angiogenesis by Abeta peptides Angiogenesis 2004 7 1 75 85 15302999
Paris D, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7(1):75–85.15302999
46. Suter OC Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease Stroke 2002 33 8 1986 1992 12154250
Suter OC, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002;33(8):1986–92.12154250
47. Kalaria RN Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia Brain Res Mol Brain Res 1998 62 1 101 105 9795165
Kalaria RN, et al. Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Res Mol Brain Res. 1998;62(1):101–5.9795165
48. Tarkowski E Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia Neurobiol Aging 2002 23 2 237 243 11804709
Tarkowski E, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging. 2002;23(2):237–43.11804709
49. Horner A Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage J Anat 1999 194 Pt 4 519 24 10445820
Horner A, et al. Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. J Anat. 1999;194(Pt 4):519–24.10445820
50. Imai K Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells Blood 1999 93 1 149 156 9864156
Imai K, et al. Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Blood. 1999;93(1):149–56.9864156
51. Imai K Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow Br J Haematol 1999 106 4 905 911 10519991
Imai K, et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 1999;106(4):905–11.10519991
52. Peled A The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice Blood 2000 95 11 3289 3296 10828007
Peled A, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95(11):3289–96.10828007
53. Tan ZS Bone mineral density and the risk of Alzheimer disease Arch Neurol 2005 62 1 107 111 15642856
Tan ZS, et al. Bone mineral density and the risk of Alzheimer disease. Arch Neurol. 2005;62(1):107–11.15642856
54. Wang HK Increased risk of hip fractures in patients with dementia: a nationwide population-based study BMC Neurol 2014 14 175 25213690
Wang HK, et al. Increased risk of hip fractures in patients with dementia: a nationwide population-based study. BMC Neurol. 2014;14:175.25213690
55. Zhao Y Shen L Ji HF Alzheimer’s disease and risk of hip fracture: a meta-analysis study Sci World J 2012 2012 872173
Zhao Y, Shen L, Ji HF. Alzheimer’s disease and risk of hip fracture: a meta-analysis study. Sci World J. 2012;2012:872173.
56. Yaffe K Association between bone mineral density and cognitive decline in older women J Am Geriatr Soc 1999 47 10 1176 1182 10522949
Yaffe K, et al. Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc. 1999;47(10):1176–82.10522949
57. Zhou R Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer’s disease Curr Alzheimer Res 2014 11 7 706 713 25115539
Zhou R, et al. Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer’s disease. Curr Alzheimer Res. 2014;11(7):706–13.25115539
58. Brownbill RA Ilich JZ Cognitive function in relation with bone mass and nutrition: cross-sectional association in postmenopausal women BMC Womens Health 2004 4 1 2 15163349
Brownbill RA, Ilich JZ. Cognitive function in relation with bone mass and nutrition: cross-sectional association in postmenopausal women. BMC Womens Health. 2004;4(1):2.15163349
59. Lary CW, et al. Bone mineral density and the risk of incident dementia: a meta-analysis. J Am Geriatr Soc. 2023.
60. Castro-Aldrete L Sex and gender considerations in Alzheimer’s disease: the Women’s Brain Project contribution Front Aging Neurosci 2023 15 1105620 37065460
Castro-Aldrete L, et al. Sex and gender considerations in Alzheimer’s disease: the Women’s Brain Project contribution. Front Aging Neurosci. 2023;15:1105620.37065460
61. Janicki SC Schupf N Hormonal influences on cognition and risk for Alzheimer’s disease Curr Neurol Neurosci Rep 2010 10 5 359 366 20535591
Janicki SC, Schupf N. Hormonal influences on cognition and risk for Alzheimer’s disease. Curr Neurol Neurosci Rep. 2010;10(5):359–66.20535591
62. Lebrun CE Endogenous oestrogens are related to cognition in healthy elderly women Clin Endocrinol (Oxf) 2005 63 1 50 55 15963061
Lebrun CE, et al. Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf). 2005;63(1):50–5.15963061
63. Hoskin EK Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease Neurobiol Aging 2004 25 2 141 147 14749131
Hoskin EK, et al. Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease. Neurobiol Aging. 2004;25(2):141–7.14749131
64. Yaffe K Cognitive decline in women in relation to non-protein-bound oestradiol concentrations Lancet 2000 356 9231 708 712 11085689
Yaffe K, et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000;356(9231):708–12.11085689
65. Schupf N Onset of dementia is associated with age at menopause in women with Down’s syndrome Ann Neurol 2003 54 4 433 438 14520653
Schupf N, et al. Onset of dementia is associated with age at menopause in women with Down’s syndrome. Ann Neurol. 2003;54(4):433–8.14520653
66. Barrett-Connor E Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study J Am Geriatr Soc 1999 47 6 685 691 10366167
Barrett-Connor E, et al. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc. 1999;47(6):685–91.10366167
67. Geerlings MI Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study Ann Neurol 2003 53 5 607 615 12730994
Geerlings MI, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol. 2003;53(5):607–15.12730994
68. Cheng CH, Chen LR, Chen KH. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. 2022;23(3):1376. 10.3390/ijms23031376.
69. Henderson VW Estrogens, episodic memory, and Alzheimer’s disease: a critical update Semin Reprod Med 2009 27 3 283 293 19401959
Henderson VW. Estrogens, episodic memory, and Alzheimer’s disease: a critical update. Semin Reprod Med. 2009;27(3):283–93.19401959
70. Eastell R Postmenopausal osteoporosis Nat Rev Dis Primers 2016 2 16069 27681935
Eastell R, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.27681935
71. Abu-Amer Y NF-kappaB signaling and bone resorption Osteoporos Int 2013 24 9 2377 2386 23468073
Abu-Amer Y. NF-kappaB signaling and bone resorption. Osteoporos Int. 2013;24(9):2377–86.23468073
72. Manolagas SC Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 2000 21 2 115 137 10782361
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–37.10782361
73. Riggs BL Khosla S Melton LJ 3rd A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men J Bone Miner Res 1998 13 5 763 773 9610739
Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763–73.9610739
74. Manolagas SC O'Brien CA Almeida M The role of estrogen and androgen receptors in bone health and disease Nat Rev Endocrinol 2013 9 12 699 712 24042328
Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699–712.24042328
75. Katznelson L Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism J Clin Endocrinol Metab 1996 81 12 4358 4365 8954042
Katznelson L, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81(12):4358–65.8954042
76. Daniell HW Osteoporosis after orchiectomy for prostate cancer J Urol 1997 157 2 439 444 8996327
Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157(2):439–44.8996327
77. Falahati-Nini A Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 2000 106 12 1553 1560 11120762
Falahati-Nini A, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106(12):1553–60.11120762
78. Lee K Endocrinology: bone adaptation requires oestrogen receptor-alpha Nature 2003 424 6947 389 12879058
Lee K, et al. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature. 2003;424(6947):389.12879058
79. •• Xiong J, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature 2022;603(7901):470–476. This study shows the potential of FSH blocking as a new treatment for AD, as this treatment in mice led to a reduction of AD phenotype.
80. Geng W Immunization with FSHbeta fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model Biochem Biophys Res Commun 2013 434 2 280 286 23537645
Geng W, et al. Immunization with FSHbeta fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model. Biochem Biophys Res Commun. 2013;434(2):280–6.23537645
81. Ji Y Epitope-specific monoclonal antibodies to FSHbeta increase bone mass Proc Natl Acad Sci U S A 2018 115 9 2192 2197 29440419
Ji Y, et al. Epitope-specific monoclonal antibodies to FSHbeta increase bone mass. Proc Natl Acad Sci U S A. 2018;115(9):2192–7.29440419
82. Liu P Blocking FSH induces thermogenic adipose tissue and reduces body fat Nature 2017 546 7656 107 112 28538730
Liu P, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature. 2017;546(7656):107–12.28538730
83. • Gera S, et al. FSH-blocking therapeutic for osteoporosis. Elife. 2022;11:e78022. 10.7554/eLife.78022. This study discussed the efficacy of FSH blockade in osteoporosis treatment in mice and introduced a new FSH-blocking antibody to be used in human trials.
84. Heneka MT Neuroinflammation in Alzheimer’s disease Lancet Neurol 2015 14 4 388 405 25792098
Heneka MT, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.25792098
85. Guerreiro R TREM2 variants in Alzheimer’s disease N Engl J Med 2013 368 2 117 127 23150934
Guerreiro R, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.23150934
86. Bradshaw EM CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology Nat Neurosci 2013 16 7 848 850 23708142
Bradshaw EM, et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16(7):848–50.23708142
87. Griciuc A Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron 2013 78 4 631 643 23623698
Griciuc A, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–43.23623698
88. Jadhav VS Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice Mol Neurodegener 2020 15 1 62 33115519
Jadhav VS, et al. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol Neurodegener. 2020;15(1):62.33115519
89. Lee-Gosselin A, et al. TREM2-deficient microglia attenuate tau spreading in vivo. Cells. 2023;12(12):1597. 10.3390/cells12121597.
90. Olabarria M Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener 2011 6 55 21801442
Olabarria M, et al. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55.21801442
91. Kovacs GG Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy Acta Neuropathol 2016 131 1 87 102 26659578
Kovacs GG, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87–102.26659578
92. McGeer PL McGeer EG The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases Brain Res Brain Res Rev 1995 21 2 195 218 8866675
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195–218.8866675
93. McGeer PL Rogers J Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease Neurology 1992 42 2 447 449 1736183
McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology. 1992;42(2):447–9.1736183
94. Otero K TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis J Immunol 2012 188 6 2612 2621 22312126
Otero K, et al. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188(6):2612–21.22312126
95. Humphrey MB TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function J Bone Miner Res 2006 21 2 237 245 16418779
Humphrey MB, et al. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res. 2006;21(2):237–45.16418779
96. Essex AL Triggering receptor expressed on myeloid cells 2 (TREM2) R47H variant causes distinct age- and sex-dependent musculoskeletal alterations in mice J Bone Miner Res 2022 37 7 1366 1381 35575023
Essex AL, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) R47H variant causes distinct age- and sex-dependent musculoskeletal alterations in mice. J Bone Miner Res. 2022;37(7):1366–81.35575023
97. Chen X Guo C Kong J Oxidative stress in neurodegenerative diseases Neural Regen Res 2012 7 5 376 385 25774178
Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012;7(5):376–85.25774178
98. Cassidy L Oxidative stress in Alzheimer’s disease: a review on emergent natural polyphenolic therapeutics Complement Ther Med 2020 49 102294 32147039
Cassidy L, et al. Oxidative stress in Alzheimer’s disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49:102294.32147039
99. Gella A Durany N Oxidative stress in Alzheimer disease Cell Adh Migr 2009 3 1 88 93 19372765
Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adh Migr. 2009;3(1):88–93.19372765
100. Valko M Morris H Cronin MT Metals, toxicity and oxidative stress Curr Med Chem 2005 12 10 1161 1208 15892631
Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12(10):1161–208.15892631
101. Mark RJ A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide J Neurochem 1997 68 1 255 264 8978733
Mark RJ, et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem. 1997;68(1):255–64.8978733
102. Bradley-Whitman MA Lovell MA Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update Arch Toxicol 2015 89 7 1035 1044 25895140
Bradley-Whitman MA, Lovell MA. Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol. 2015;89(7):1035–44.25895140
103. Keller JN Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal J Neurochem 1997 69 1 273 284 9202320
Keller JN, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem. 1997;69(1):273–84.9202320
104. Mattson MP Chan SL Neuronal and glial calcium signaling in Alzheimer’s disease Cell Calcium 2003 34 4–5 385 397 12909083
Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer’s disease. Cell Calcium. 2003;34(4–5):385–97.12909083
105. Tamagno E H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK Exp Neurol 2003 180 2 144 155 12684028
Tamagno E, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol. 2003;180(2):144–55.12684028
106. Kimball JS Johnson JP Carlson DA Oxidative stress and osteoporosis J Bone Joint Surg Am 2021 103 15 1451 1461 34014853
Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Joint Surg Am. 2021;103(15):1451–61.34014853
107. Fontani F Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling Calcif Tissue Int 2015 96 4 335 346 25660312
Fontani F, et al. Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling. Calcif Tissue Int. 2015;96(4):335–46.25660312
108. Filaire E Toumi H Reactive oxygen species and exercise on bone metabolism: friend or enemy? Joint Bone Spine 2012 79 4 341 346 22578961
Filaire E, Toumi H. Reactive oxygen species and exercise on bone metabolism: friend or enemy? Joint Bone Spine. 2012;79(4):341–6.22578961
109. Romagnoli C Role of GSH/GSSG redox couple in osteogenic activity and osteoclastogenic markers of human osteoblast-like SaOS-2 cells FEBS J 2013 280 3 867 879 23176170
Romagnoli C, et al. Role of GSH/GSSG redox couple in osteogenic activity and osteoclastogenic markers of human osteoblast-like SaOS-2 cells. FEBS J. 2013;280(3):867–79.23176170
110. Bai XC Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB Biochem Biophys Res Commun 2004 314 1 197 207 14715266
Bai XC, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun. 2004;314(1):197–207.14715266
111. Bellido T Osteocyte-driven bone remodeling Calcif Tissue Int 2014 94 1 25 34 24002178
Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int. 2014;94(1):25–34.24002178
112. Bonewald LF The amazing osteocyte J Bone Miner Res 2011 26 2 229 238 21254230
Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38.21254230
113. Jilka RL Noble B Weinstein RS Osteocyte apoptosis Bone 2013 54 2 264 271 23238124
Jilka RL, Noble B, Weinstein RS. Osteocyte apoptosis. Bone. 2013;54(2):264–71.23238124
114. Al-Dujaili SA Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro J Cell Biochem 2011 112 9 2412 2423 21538477
Al-Dujaili SA, et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem. 2011;112(9):2412–23.21538477
115. Mulcahy LE RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells Bone 2011 48 2 182 188 20854946
Mulcahy LE, et al. RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone. 2011;48(2):182–8.20854946
116. Singh R, Sadiq NM. Cholinesterase inhibitors. In: StatPearls. Treasure Island (FL); 2023.https://www.ncbi.nlm.nih.gov/books/NBK544336/. Accessed 19 Sept 2023.
117. Eldufani J Blaise G The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications Alzheimers Dement (N Y) 2019 5 175 183 31194017
Eldufani J, Blaise G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications. Alzheimers Dement (N Y). 2019;5:175–83.31194017
118. Sharma K Cholinesterase inhibitors as Alzheimer’s therapeutics (Review) Mol Med Rep 2019 20 2 1479 1487 31257471
Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol Med Rep. 2019;20(2):1479–87.31257471
119. Wang R Reddy PH Role of glutamate and NMDA receptors in Alzheimer’s disease J Alzheimers Dis 2017 57 4 1041 1048 27662322
Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis. 2017;57(4):1041–8.27662322
120. Kuns B, Rosani A, Varghese D. Memantine. In: StatPearls. Treasure Island (FL); 2023. https://www.ncbi.nlm.nih.gov/books/NBK500025/. Accessed 19 Sept 2023.
121. Passeri E, et al. Alzheimer’s disease: treatment strategies and their limitations. Int J Mol Sci. 2022;23(22):13954. 10.3390/ijms232213954.
122. Crous-Bou M Alzheimer’s disease prevention: from risk factors to early intervention Alzheimers Res Ther 2017 9 1 71 28899416
Crous-Bou M, et al. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017;9(1):71.28899416
123. Beshir SA Aducanumab therapy to treat Alzheimer’s disease: a narrative review Int J Alzheimers Dis 2022 2022 9343514 35308835
Beshir SA, et al. Aducanumab therapy to treat Alzheimer’s disease: a narrative review. Int J Alzheimers Dis. 2022;2022:9343514.35308835
124. Tonk CH, et al. Therapeutic treatments for osteoporosis-which combination of pills is the best among the bad? Int J Mol Sci. 2022;23(3):1393. 10.3390/ijms23031393.
125. Nicholls AR Holt RI Growth hormone and insulin-like growth factor-1 Front Horm Res 2016 47 101 114 27347885
Nicholls AR, Holt RI. Growth hormone and insulin-like growth factor-1. Front Horm Res. 2016;47:101–14.27347885
126. de Vernejoul MC Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men Clin Orthop Relat Res 1983 179 107 15
de Vernejoul MC, et al. Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men. Clin Orthop Relat Res. 1983;179:107–15.
127. Russow G, et al. Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci. 2018;20(1):83. 10.3390/ijms20010083.
128. Bi H Key triggers of osteoclast-related diseases and available strategies for targeted therapies: a review Front Med (Lausanne) 2017 4 234 29326938
Bi H, et al. Key triggers of osteoclast-related diseases and available strategies for targeted therapies: a review. Front Med (Lausanne). 2017;4:234.29326938
129. Makino A Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide Calcif Tissue Int 2018 103 3 289 297 29725706
Makino A, et al. Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide. Calcif Tissue Int. 2018;103(3):289–97.29725706
130. • Zhang M, Hu S, Sun X. Alzheimer’s disease and impaired bone microarchitecture, regeneration and potential genetic links. Life (Basel). 2023;13(2):373. 10.3390/life13020373. This is a comprehensive review article that explores mechanisms and genetic influences shared between AD and osteoporosis.
131. Melton LJ 3rd Fracture risk in patients with Alzheimer’s disease J Am Geriatr Soc 1994 42 6 614 619 8201146
Melton LJ 3rd, et al. Fracture risk in patients with Alzheimer’s disease. J Am Geriatr Soc. 1994;42(6):614–9.8201146
132. Tolppanen AM Incident hip fractures among community dwelling persons with Alzheimer’s disease in a Finnish nationwide register-based cohort PLoS ONE 2013 8 3 e59124 23527106
Tolppanen AM, et al. Incident hip fractures among community dwelling persons with Alzheimer’s disease in a Finnish nationwide register-based cohort. PLoS ONE. 2013;8(3):e59124.23527106
133. Amboni M Barone P Hausdorff JM Cognitive contributions to gait and falls: evidence and implications Mov Disord 2013 28 11 1520 1533 24132840
Amboni M, Barone P, Hausdorff JM. Cognitive contributions to gait and falls: evidence and implications. Mov Disord. 2013;28(11):1520–33.24132840
134. Sato Y Risk factors for hip fracture among elderly patients with Alzheimer’s disease J Neurol Sci 2004 223 2 107 112 15337610
Sato Y, et al. Risk factors for hip fracture among elderly patients with Alzheimer’s disease. J Neurol Sci. 2004;223(2):107–12.15337610
135. Kipen E Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia J Am Geriatr Soc 1995 43 10 1088 1091 7560696
Kipen E, et al. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc. 1995;43(10):1088–91.7560696
136. Morrison RS Siu AL Mortality from pneumonia and hip fractures in patients with advanced dementia JAMA 2000 284 19 2447 2448 11074771
Morrison RS, Siu AL. Mortality from pneumonia and hip fractures in patients with advanced dementia. JAMA. 2000;284(19):2447–8.11074771
137. Holmes JD House AO Psychiatric illness in hip fracture Age Ageing 2000 29 6 537 546 11191247
Holmes JD, House AO. Psychiatric illness in hip fracture. Age Ageing. 2000;29(6):537–46.11191247
138. Matsueda M Ishii Y The relationship between dementia score and ambulatory level after hip fracture in the elderly Am J Orthop (Belle Mead NJ) 2000 29 9 691 693 11008865
Matsueda M, Ishii Y. The relationship between dementia score and ambulatory level after hip fracture in the elderly. Am J Orthop (Belle Mead NJ). 2000;29(9):691–3.11008865
139. Tanaka S The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women–a joint analysis of the Nagano, Miyama, and Taiji Cohorts Bone 2010 47 6 1064 1070 20832514
Tanaka S, et al. The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women–a joint analysis of the Nagano, Miyama, and Taiji Cohorts. Bone. 2010;47(6):1064–70.20832514
140. Baker NL Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988–2007 Age Ageing 2011 40 1 49 54 21087990
Baker NL, et al. Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988–2007. Age Ageing. 2011;40(1):49–54.21087990
141. Bukata SV Kates SL O'Keefe RJ Short-term and long-term orthopaedic issues in patients with fragility fractures Clin Orthop Relat Res 2011 469 8 2225 2236 21279487
Bukata SV, Kates SL, O’Keefe RJ. Short-term and long-term orthopaedic issues in patients with fragility fractures. Clin Orthop Relat Res. 2011;469(8):2225–36.21279487
142. Gleason LJ Diagnosis and treatment of osteoporosis in high-risk patients prior to hip fracture Geriatr Orthop Surg Rehabil 2012 3 2 79 83 23569701
Gleason LJ, et al. Diagnosis and treatment of osteoporosis in high-risk patients prior to hip fracture. Geriatr Orthop Surg Rehabil. 2012;3(2):79–83.23569701
143. Kim SY Increased risk of dementia after distal radius, hip, and spine fractures Medicine (Baltimore) 2020 99 10 e19048 32150051
Kim SY, et al. Increased risk of dementia after distal radius, hip, and spine fractures. Medicine (Baltimore). 2020;99(10):e19048.32150051
144. Goto S Relationship between cognitive function and balance in a community-dwelling population in Japan Acta Otolaryngol 2018 138 5 471 474 29205084
Goto S, et al. Relationship between cognitive function and balance in a community-dwelling population in Japan. Acta Otolaryngol. 2018;138(5):471–4.29205084
145. Deschamps T Postural control and cognitive decline in older adults: position versus velocity implicit motor strategy Gait Posture 2014 39 1 628 630 23891457
Deschamps T, et al. Postural control and cognitive decline in older adults: position versus velocity implicit motor strategy. Gait Posture. 2014;39(1):628–30.23891457
146. Bahureksa L The impact of mild cognitive impairment on gait and balance: a systematic review and meta-analysis of studies using instrumented assessment Gerontology 2017 63 1 67 83 27172932
Bahureksa L, et al. The impact of mild cognitive impairment on gait and balance: a systematic review and meta-analysis of studies using instrumented assessment. Gerontology. 2017;63(1):67–83.27172932
147. Kristinsdottir EK Jarnlo GB Magnusson M Asymmetric vestibular function in the elderly might be a significant contributor to hip fractures Scand J Rehabil Med 2000 32 2 56 60 10853718
Kristinsdottir EK, Jarnlo GB, Magnusson M. Asymmetric vestibular function in the elderly might be a significant contributor to hip fractures. Scand J Rehabil Med. 2000;32(2):56–60.10853718
148. Kristinsdottir EK Observation of vestibular asymmetry in a majority of patients over 50 years with fall-related wrist fractures Acta Otolaryngol 2001 121 4 481 485 11508508
Kristinsdottir EK, et al. Observation of vestibular asymmetry in a majority of patients over 50 years with fall-related wrist fractures. Acta Otolaryngol. 2001;121(4):481–5.11508508
149. Ekvall Hansson E Dahlberg LE Magnusson M Vestibular rehabilitation affects vestibular asymmetry among patients with fall-related wrist fractures - a randomized controlled trial Gerontology 2015 61 4 310 8 25471256
Ekvall Hansson E, Dahlberg LE, Magnusson M. Vestibular rehabilitation affects vestibular asymmetry among patients with fall-related wrist fractures - a randomized controlled trial. Gerontology. 2015;61(4):310–8.25471256
150. Yu MD Su BH Zhang XX Morphologic and molecular alteration during tibia fracture healing in rat Eur Rev Med Pharmacol Sci 2018 22 5 1233 1240 29565479
Yu MD, Su BH, Zhang XX. Morphologic and molecular alteration during tibia fracture healing in rat. Eur Rev Med Pharmacol Sci. 2018;22(5):1233–40.29565479
151. Hall RJ Cerebrospinal fluid levels of neopterin are elevated in delirium after hip fracture J Neuroinflammation 2016 13 1 170 27357281
Hall RJ, et al. Cerebrospinal fluid levels of neopterin are elevated in delirium after hip fracture. J Neuroinflammation. 2016;13(1):170.27357281
152. Neerland BE Associations between delirium and preoperative cerebrospinal fluid C-reactive protein, interleukin-6, and interleukin-6 receptor in individuals with acute hip fracture J Am Geriatr Soc 2016 64 7 1456 1463 27341529
Neerland BE, et al. Associations between delirium and preoperative cerebrospinal fluid C-reactive protein, interleukin-6, and interleukin-6 receptor in individuals with acute hip fracture. J Am Geriatr Soc. 2016;64(7):1456–63.27341529
153. Darweesh SKL Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis Alzheimers Dement 2018 14 11 1450 1459 29605221
Darweesh SKL, et al. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimers Dement. 2018;14(11):1450–9.29605221
154. Yeler H Tahtabas F Candan F Investigation of oxidative stress during fracture healing in the rats Cell Biochem Funct 2005 23 2 137 139 15651080
Yeler H, Tahtabas F, Candan F. Investigation of oxidative stress during fracture healing in the rats. Cell Biochem Funct. 2005;23(2):137–9.15651080
155. Mecocci P A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks J Alzheimers Dis 2018 62 3 1319 1335 29562533
Mecocci P, et al. A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. J Alzheimers Dis. 2018;62(3):1319–35.29562533
156. Piirtola M Fractures as an independent predictor of functional decline in older people: a population-based study with an 8-year follow-up Gerontology 2012 58 4 296 304 22205067
Piirtola M, et al. Fractures as an independent predictor of functional decline in older people: a population-based study with an 8-year follow-up. Gerontology. 2012;58(4):296–304.22205067
157. Olofsson B Development of dementia in patients with femoral neck fracture who experience postoperative delirium-a three-year follow-up study Int J Geriatr Psychiatry 2018 33 4 623 632 29292537
Olofsson B, et al. Development of dementia in patients with femoral neck fracture who experience postoperative delirium-a three-year follow-up study. Int J Geriatr Psychiatry. 2018;33(4):623–32.29292537
